Regulation of mRNAs encoding MMP-9 and MMP-2, and their inhibitors TIMP-1 and TIMP-2 by androgens in the rat ventral prostate

Molecular and Cellular Endocrinology

Volumn 294, Issue 1-2, 2008, Pages 10-18

  Limaye, Anil M ^a   Desai, Kartiki V ^a   Chavalmane, Aravinda K ^a   Kondaiah, Paturu ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Actinomycin D; Antiandrogen; Castration; Flutamide; MMP; TIMP

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; DACTINOMYCIN; FLUTAMIDE; GELATINASE A; GELATINASE B; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

3' UNTRANSLATED REGION; ANIMAL TISSUE; ARTICLE; CASTRATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME INDUCTION; ENZYME REGULATION; GENE EXPRESSION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE VENTRAL LOBE; PROTEIN RNA BINDING; RAT;

ANDROGENS; ANIMALS; BASE SEQUENCE; BLOTTING, NORTHERN; CASTRATION; DACTINOMYCIN; FLUTAMIDE; GELATIN; GENE EXPRESSION REGULATION, ENZYMOLOGIC; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MOLECULAR SEQUENCE DATA; PROSTATE; PROTEIN BINDING; RATS; RATS, WISTAR; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSCRIPTION, GENETIC;

EID: 53649105861     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.07.003     Document Type: Article

References (38)

1. Assikis V.J., Do K.A., Wen S., Wang X., Cho-Vega J.H., Brisbay S., Lopez R., Logothetis C.J., Troncoso P., Papandreou C.N., and McDonnell T.J. Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. Clin. Cancer Res. 10 (2004) 6770-6778
2. Baum C.L., and Arpey C.J. Normal cutaneous wound healing: clinical correlation with cellular and molecular events. Dermatol. Surg. 31 (2005) 674-686
3. Bode W., Reinemer P., Huber R., Kleine T., Schnierer S., and Tschesche H. The X-ray crystal structure of the catalytic domain human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. EMBO J. 13 (1994) 1263-1269
4. Bratland A., Ragnhildstveit E., Bjornland K., Andersen K., Maelandsmo G.M., Fodstad O., Saatcioglu F., and Ree A.H. The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cells. Clin. Exp. Metastasis 20 (2003) 541-547
5. Church G.M., and Gilbert W. Genomic sequencing. Proc. Natl. Acad. Sci. U.S.A. 81 (1984) 1991-1995
6. Desai K.V., and Kondaiah P. Androgen ablation results in differential regulation of transforming growth factor-beta isoforms in rat male accessory sex organs and epididymis. J. Mol. Endocrinol. 24 (2000) 253-260
7. Fata J.E., Werb Z., and Bissel M.J. Regulation of mammary gland branching morphogenesis by the extracellular matrix and its remodeling enzymes. Breast Cancer Res. 6 (2004) 1-11
8. Galis Z.S., and Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res. 90 (2002) 251-262
9. Goldberg G.I., Marmer B.L., Grant G.A., Eisen A.Z., Wilhelm S., and He C.S. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloprotease designated TIMP-2. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 8207-8211
10. Hamdy F.C., Fadlon E.J., Cottam D., Lawry J., Thurrel W., Silcocks P.B., Anderson J.B., Williams J.L., and Rees R.C. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br. J. Cancer 69 (1994) 177-182
11. Heckert L.L., Wilson E.M., and Nilson J.H. Transcriptional repression of the alpha-subunit gene by androgen receptor occurs independently of DNA binding but requires the DNA-binding and ligand-binding domains of the receptor. Mol. Endocrinol. 11 (1997) 1497-1506
12. Itoh N., Patel U., Cupp A.S., and Skinner M.K. Developmental and hormonal regulation of transforming growth factor beta-1, -2, and -3 gene expression in isolated prostatic epithelial and stromal cells: epidermal growth factor and TGF-beta interactions. Endocrinology 139 (1998) 1378-1388
13. Kyprianou N., and Isaacs J.T. Expression of transforming growth factor beta in the rat ventral prostate during castration induced programmed cell death. Mol. Endocrinol. 3 (1989) 1515-1522
14. Leger J.G., Montpetit M.L., and Tenniswood M.P. Characterization and cloning of androgen-repressed mRNAs from rat ventral prostate. Biochem. Biophys. Res. Commun. 147 (1987) 196-203
15. Li B.Y., Liao X.B., Fujito A., Thrasher J.B., Shen F.Y., and Xu P.Y. Dual androgen-response elements mediate androgen regulation of MMP-2 expression in prostate cancer cells. Asian J. Androl. 9 (2007) 41-50
16. Lichtinghagen R., Musholt P.B., Lein M., Romer A., Rudolph B., Kristiansen G., Hauptmann S., Schnorr D., Loening S.A., and Jung K. Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. Eur. Urol. 42 (2002) 398-406
17. Lichtinghagen R., Musholt P.B., Stephan C., Lein M., Kristiansen G., Houptman S., Rudolph B., Schnorr D., Loening S.A., and Jung K. mRNA expression profile of matrix metalloproteinases and their tissue inhibitors in malignant and non-malignant prostatic tissue. Anticancer Res. 23 (2003) 2617-2624
18. Lijnen H.R. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb. Haemost. 86 (2001) 324-333
19. Limaye A.M., Asangani I., Kalyani T., and Kondaiah P. Changes in gene expression following androgen receptor blockade is not equivalent to androgen ablation by castration in the rat ventral prostate. J. Biosci. 33 (2008) 209-220
20. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
21. Montalvo L., Sanchez-Chapado M., Prieto J.C., and Carmena M.J. Regulation of the expression of protein kinase C isoenzymes in rat ventral prostate: effects of age, castration and flutamide treatment. Life Sci. 71 (2002) 2257-2266
22. Nagase H., and Woessner Jr. J.F. Matrix metalloproteinases. J. Biol. Chem. 274 (1999) 21491-21494
23. Nishi N., Oya H., Matsumoto K., Nakamura T., Miyanaka H., and Wada F. Changes in gene expression of growth factors and their receptors during castration-induced involution and androgen-induced regrowth of rat prostates. Prostate 28 (1996) 139-152
24. Ohnishi J., Ohnishi E., Shibuya H., and Takahashi T. Functions for proteinases in the ovulatory process. Biochim. Biophys. Acta 1751 (2005) 95-109
25. Page M., and Parker M.G. Effect of androgen on the transcription of rat prostatic binding protein genes. Mol. Cell Endocrinol. 27 (1982) 343-355
26. Pajough S., Nagle R.B., Breathnach R., Finch J.S., Brawer M.K., and Bowden G.T. Expression of metalloproteinase genes in human prostate cancer. J. Cancer Res. Clin. Oncol. 117 (1991) 144-150
27. Powell W.C., Domann Jr. F.E., Mitchen J.M., Matrisian L.M., Nagle R.B., and Bowden G.T. Matrilysin expression in the involuting rat ventral prostate. Prostate 29 (1996) 159-168
28. Russo P., Warner J.A., Huryk R., Perez G., and Heston W.D. TRPM-2 gene expression in normal rat ventral prostate following castration and exposure to diethylstilbestrol, flutamide, MK-906 (finasteride), and coumarin. Prostate 24 (1994) 237-243
29. Saarialho-Kere U.K., Pentland A.P., Birkedal-Hansen H., Parks W.C., and Welgus H.G. Distinct populations of basal keratinocytes express stromelysin-1 and stromelysin-2 in chronic wounds. J. Clin. Invest. 94 (1994) 79-88
30. Schneikert J., Peterziel H., Defossez P.A., Klocker H., Launoit Y., and Cato A.C. Androgen receptor-Ets protein interaction is a novel mechanism for steroid hormone-mediated down-modulation of matrix metalloproteinase expression. J. Biol. Chem. 271 (1996) 23907-23913
31. Szklarczyk A., Lapinska J., Rylski M., McKay R.D., and Kaczmarek L. Matrix metalloproteinse-9 undergoes expression and activation during dendritic remodeling in adult hippocampus. J. Neurosci. 22 (2002) 920-930
32. Wilson M.J. Proteases in prostate development, function and pathology. Microsc. Res. Tech. 30 (1995) 305-318
33. Wilson M.J., Ludowese C., Sinha A.A., and Estensen R.D. Effects of castration on plasminogen activities and plasminogen activator inhibitor type I in the rat ventral prostate. Prostate 28 (1996) 239-250
34. Yan L., Borregaard N., Kjeldsen L., and Moses M.A. The high molecular weight urinary matrix metalloproteases (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J. Biol. Chem. 276 (2001) 37258-37265
35. Yeap B.B., Voon D.C., Vivian J.P., McCulloch R.K., Thomson A.M., Giles K.M., Czyzyk-Krzeska M.F., Furneaux H., Wilce M.C., Wilce J.A., and Leedman P.J. Novel binding of HuR and poly(C)-binding protein to a conserved UC-rich motif within the 3'-untranslated region of the androgen receptor messenger RNA. J. Biol. Chem. 277 (2002) 27183-27192
36. Zeng H., Xiao Y., Lu G., and Chen Y. Immunohistochemical studies of the expression of matrix metalloproteinase-2 and metalloproteinase-9 in human prostate cancer. J. Huazhong Univ. Sci. Technol. Med. Sci. 23 373-374 (2003) 379
37. Zhang M., Magit D., and Sager R. Expression of maspin in prostate cells is regulated by a positive Ets element and a negative hormonal responsive element site recognized by androgen receptor. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 5673-5678
38. Zhang X., and Nothnick W.B. The role and regulation of the uterine matrix metalloproteinase system in menstruating and non-menstruating species. Front. Biosci. 10 (2005) 353-366